Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Net Income (2023 - 2025)

Historic Net Income for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to -$60.1 million.

  • Immunome's Net Income fell 1903.33% to -$60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 2622.53%. This contributed to the annual value of -$305.8 million for FY2024, which is 17919.29% down from last year.
  • Per Immunome's latest filing, its Net Income stood at -$60.1 million for Q3 2025, which was down 1903.33% from -$46.5 million recorded in Q2 2025.
  • Immunome's 5-year Net Income high stood at -$4.5 million for Q1 2023, and its period low was -$132.3 million during Q1 2024.
  • Moreover, its 3-year median value for Net Income was -$46.5 million (2025), whereas its average is -$51.5 million.
  • As far as peak fluctuations go, Immunome's Net Income plummeted by 285904.72% in 2024, and later surged by 6626.13% in 2025.
  • Immunome's Net Income (Quarter) stood at -$94.7 million in 2023, then increased by 12.34% to -$83.0 million in 2024, then increased by 27.52% to -$60.1 million in 2025.
  • Its Net Income was -$60.1 million in Q3 2025, compared to -$46.5 million in Q2 2025 and -$44.6 million in Q1 2025.